RxDoctor Payments Data

Komal Patel, PA

Medical · Raleigh, NCNPI 1154666238

Payments from drug & device makers

$6,824in general payments, 2019–2025

Across 371 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$930
  • Abbott$783
  • Lilly USA, LLC$574
  • Amgen$353
  • AbbVie$305
  • Boehringer Ingelheim$302
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$6,77099%
  • Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,824 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$40,884
Medicare patients
102
Services billed
1,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide24$102,185
OzempicSemaglutide38$63,042
MounjaroTirzepatide34$54,116
ProliaDenosumab21$36,285
JardianceEmpagliflozin27$34,232
Xultophy 100-3.6Insulin Degludec/Liraglutide13$27,410
Tresiba Flextouch U-200Insulin Degludec16$20,636
TrulicityDulaglutide11$13,659
Lyumjev Kwikpen U-100Insulin Lispro-Aabc21$12,224
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$7,656
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$4,783
Tresiba Flextouch U-100Insulin Degludec11$4,069
VascepaIcosapent Ethyl11$3,835
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,661
Novolog FlexpenInsulin Aspart19$2,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo, Mounjaro, Trulicity$574$169,96069 claims
Novo NordiskOzempic, Xultophy 100-3.6$930$90,45251 claims
AmgenProlia$353$36,28521 claims
Boehringer IngelheimJardiance$302$34,23227 claims
AbbVieSynthroid$305$1,94120 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$60$1,13889 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.

Other medical in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →